Latest News Archive

Please select Category, Year, and then Month to display items

#UFSYouthMonth2024: Empowering youth to tackle mental health

18 June 2024 | Story Valentino Ndaba | Photo iStock

Mental health 2024 — The University of the Free State celebrates Youth Month by promoting mental health, inspired by the resilient spirit of 1976.

To commemorate Youth Month 2024, the University of the Free State (UFS) highlights the strides made by its youth in addressing mental health challenges. The Department of Student Counselling and Development (SCD) plays a crucial role in empowering students to be well-being warriors, drawing inspiration from the resilience and determination of the youth of 1976.

The spirit of 1976

This year marks the 48th anniversary of the Soweto Uprising, where youth bravely protested against apartheid's oppressive education system, igniting a movement for freedom and justice in South Africa. As we commemorate National Youth Day on 16 June 2024, with the theme “Actively advancing socioeconomic gains of our democracy,” we reflect on this legacy and celebrate 30 years of freedom by empowering today’s youth to overcome modern challenges. This aligns with the UFS’s commitment to Vision 130, which emphasises care, well-being, and inclusivity, creating a supportive environment for teaching, learning, and community engagement.

Empowering students for mental well-being

Dr Munita Dunn-Coetzee, Director of SCD at UFS, underscores the department’s mission: “Student Counselling and Development aims to implement holistic mental health services that promote student well-being and assist students to flourish. We want students to become Well-being Warriors, raising awareness and providing education about what mental health really means, and how it contributes to overall well-being. Our goal is to enhance students' resilience through a variety of support services.”

SCD’s empowering role is realised through an array of services including self-help materials, workshops and group and individual therapy sessions. These initiatives are designed to foster a compassionate and caring environment conducive to mental well-being.

Success stories

The impact of SCD is best illustrated through the transformation seen in students who have utilised its resources. Dr Dunn-Coetzee recounts: “A success story is when you start seeing a behaviour change – the way a student looks, dresses, talks, the sparkle in their eye returning. This positive transformation is often shared with peers, creating a ripple effect of empowerment and resilience.”

One SCD influencer who acts as a Well-being Warrior, Tsholofelo Mahamotse, reflects on her journey: “Utilising the university’s student counselling services has profoundly empowered me to address my mental health challenges. The resources and support available provided a safe space to express my concerns and work through them with professional guidance. This support has not only helped me navigate difficult times but also fostered personal growth and a deeper understanding of self-care.”

Comprehensive approach to student support

SCD offers a spectrum of essential services for student well-being, including individual psychotherapy and group workshops on stress management, self-esteem, and emotional intelligence; support for developing key personality traits and professional skills; career guidance through psychometric tools; and academic support to enhance study skills and manage test anxiety and time effectively.

Empowerment through support

Mahamotse urges fellow students: “I encourage you to take full advantage of the mental health services our university provides. Seeking help is a sign of strength, and utilising these resources can make a tremendous difference in your overall well-being. Support is just a step away.”

As UFS commemorates Youth Month, it celebrates not just the legacy of past youth movements but also the present-day efforts of youth who continue to build a better future through resilience, courage, and empowerment.

Celebrating Youth Month at UFS

Community Engagement Office: Youth Day Celebration

Date: 21 June 2024

Time: 09:00–14:00

Venue: Lusaka Community Hall, Qwaqwa

Topics: Gender-based violence; bullying; LGBTQ, legislative framework, substance abuse, crime, school dropout; teenage pregnancy, youth unemployment, and child-headed households.

Services: Contraceptives, sexually transmitted illness treatment, voluntary medical male circumcision, and referrals.

For more information, contact Moodi Matsoso at matsosoMS@ufs.ac.za.

Career Pathway

The Career Services Office offers a programme to enhance the employability of registered students. Upon completion, students earn five badges reflecting their competency and work-readiness.

For more information, contact Belinda Janeke at JanekeB@ufs.ac.za.

FutureLEAD Challenge

The FutureLEAD Challenge (FLC) is an online, voluntary leadership development programme available to all undergraduate and postgraduate students across UFS’s three campuses. The programme lasts four to seven months and utilises Blackboard for blended learning.

For more information, contact René Pelser at PelserR@ufs.ac.za.

Entrepreneurship talk and #YouthMonth Mingle

The Centre for Graduate Support will host a #YouthMonth Mingle where postgraduate students will discuss their studies and discover funding opportunities.

For more information, contact Naomi Haupt at DeValdoNE@ufs.ac.za

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease

2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013

The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.

In future further evaluation will be performed in other forms of hypocholesterolemia.

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept